<DOC>
	<DOC>NCT02985879</DOC>
	<brief_summary>The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).</brief_summary>
	<brief_title>A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy, Progressive</mesh_term>
	<criteria>Male or female subject with age 40 years or greater at the time of signed consent. Meets the criteria for possible or probable progressive supranuclear palsy (SteeleRichardsonOlszewski Syndrome). Presence of PSP symptoms for less than 5 years. Subject is able to walk 5 steps with minimal assistance (stabilization of one arm or use of cane/walker). Subject has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend). Subjects who weigh less than 44 kg (97 lbs) at screening. MMSE score less than 15 at screening. Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI). Subject resides at a skilled nursing or dementia care facility, or admission to such a facility is planned during the study period. Evidence of any clinically significant neurological disorder other than PSP. The subject has a history of or currently has schizophrenia, schizoaffective disorder or bipolar disorder according to DSMV or ICD10 criteria. Subject has had a significant illness or infection requiring medical intervention in the past 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>tauopathy</keyword>
	<keyword>PSP</keyword>
	<keyword>Steele-Richardson-Olszewski syndrome</keyword>
</DOC>